ReviewDrug design, development and therapy2025
Chinese Herbal Medicine in Hypoxic Pulmonary Hypertension Treatment: Mechanisms, Progress, and Future Directions.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hyperuricemia and Hypoxic Pulmonary Hypertension: Pathogenic Links, Clinical Evidence, and Emerging Therapeutic Insights.Cardiovascular drugs and therapy · 2026Review
- Ion channels and GPCRs as pharmacological regulators of ferroptosis and pyroptosis in metabolic diseases.Diabetology & metabolic syndrome · 2026Review
- Case Report: High altitude, young lives: unmasking pulmonary hypertension in two unique cases.Frontiers in medicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxic pulmonary hypertension (HPH) is a severe subtype of pulmonary hypertension(PH) characterized by chronic lung disease or prolonged hypoxia, leading to pulmonary vascular remodeling and right heart failure. Traditional Chinese Medicine (TCM) has garnered significant attention for its potential therapeutic effects on HPH due to its minimal side effects, multiple target actions, affordability, and cultural acceptance. Recent studies have highlighted the potential of TCM in inhibiting pulmonary artery smooth muscle cell proliferation, modulating inflammation, and oxidative stress. This review aims to explore the mechanisms of action of TCM in treating HPH, focusing on its ability to modulate key signaling pathways involved in pulmonary vascular remodeling, such as PI3K/Akt, Nrf2, NF-κB, and RhoA/ROCK. The goal is to provide a comprehensive overview of the current progress and future directions in the application of TCM for HPH treatment. TCM demonstrates significant therapeutic potential in HPH by modulating signaling pathways involved in inflammation, oxidative stress, and pulmonary vascular remodeling. Key compounds such as taxifolin glycoside, resveratrol, and salidroside have shown promising effects in inhibiting abnormal proliferation of pulmonary artery smooth muscle cells (PASMCs) and reducing oxidative stress. These mechanisms contribute to the overall efficacy of TCM in preventing and treating HPH. By modulating key signaling pathways and exerting anti-inflammatory and antioxidant effects, TCM offers a promising therapeutic approach for HPH. Further research is needed to validate the clinical efficacy and safety of TCM formulations, and to explore the underlying mechanisms through modern scientific methods. The integration of TCM with modern medicine could provide new strategies for the treatment of HPH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.